The AutoSet CS-A with PaceWave is ResMed’s most responsive ASV technology to stabilise the ventilation of adult patients exhibiting central sleep apnoea (CSA), mixed sleep apnoea and periodic breathing, with or without obstructive sleep apnoea.
Clinically studied, ResMed's pioneering PaceWave technology is the only ASV therapy to target the patient’s own recent minute ventilation (MV). PaceWave monitors the entire breath with split-second resolution to learn and predict a patient’s unique breathing pattern, rapidly responding to changes and steadily keeping your patient on target throughout the night.
Additionally, the AutoSet CS-A features the new ASVAuto mode with an automatically adjusting EPAP to automatically maintain an open upper airway.
It also provides greater peace of mind with four alarms to monitor your sensitive patients.
The comfort features of the S9 platform in combination with PaceWave’s ability to provide synchrony over a wider range of breath rates and personalised breathing, provides a new level of comfort supporting patient compliance.
Modes: CPAP, ASV and ASVAuto
Alarms: High leak, Non-Vented Mask, Low Minute Ventilation, Low SpO2
Morgenthaler TI, Gay PC, Gordon N, Brown LK. Adaptive servoventilation versus noninvasive positive pressure ventilation for central, mixed, and complex sleep apnea syndromes. Sleep. 2007;30(4):468-475.
Brown SE, Mosko SS, Davis JA, Pierce RA, Godfrey-Pixton TV. A retrospective case series of adaptive servoventilation for complex sleep apnea. J Clin Sleep Med 2011;7(2):187-195.
ASV therapy is contraindicated in patients with chronic, symptomatic heart failure (NYHA 2-4) with reduced left ventricular ejection fraction (LVEF ≤ 45%) and moderate to severe predominant central sleep apnoea.
Share this Page
Coronavirus: Stay informed
ResMed is closely monitoring and responding to the COVID-19 pandemic; the health and safety of our people, customers, business partners; and those who use our products and solutions worldwide is our top priority. Read more here.